Galantamine treatment in Alzheimer’s disease: response and long-term outcome in a routine clinical setting

BACKGROUND: In the absence of long-term, placebo-controlled studies of cholinesterase inhibitors in Alzheimer’s disease (AD), analysis of the results of open-label trials becomes crucial. This study aimed to explore the three-year effects of galantamine treatment, as well as subgroups of response an...

Descripción completa

Detalles Bibliográficos
Autores principales: Wallin, Åsa K, Wattmo, Carina, Minthon, Lennart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191869/
https://www.ncbi.nlm.nih.gov/pubmed/22003296
http://dx.doi.org/10.2147/NDT.S24196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191869/
https://www.ncbi.nlm.nih.gov/pubmed/22003296
http://dx.doi.org/10.2147/NDT.S24196

Ejemplares similares